Pioneering UK Payment Model For Incentivizing Antibiotic Development Meets Major Milestone

Shionogi and Pfizer are now in commercial discussions after their antibiotics were recommended for use via the UK’s new subscription-style payment model, which will ensure a fixed annual fee is paid to companies regardless of how many prescriptions are issued. The UK is urging other countries to offer similar incentives to help beat global antimicrobial resistance.